BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Pre-market movers]]>http://www.bloggingstocks.com/2007/12/10/pre-market-movers/http://www.bloggingstocks.com/2007/12/10/pre-market-movers/http://www.bloggingstocks.com/2007/12/10/pre-market-movers/#commentsFiled under: ,

LDK Solar (NYSE: LDK) is up 16% on news of a new contract with Q-Cells.

Novavax (NASDAQ: NVAX) is trading up 12% on a partnership with GE (NYSE: GE)'s healthcare group.

Hemispherx Biopharma (AMEX: HEB) is off 20% on a terminated license agreement with Esteve.

Red Hat (NYSE: RHT) is moving down almost 4% on a downgrade from Jefferies & Co.

Stocks may trade differently in the pre-market than they do in the regular session.

Douglas A. McIntyre is an editor at 247wallst.com.

Pre-market movers originally appeared on BloggingStocks on Mon, 10 Dec 2007 08:27:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>HEBHemispherx BiopharmaHemispherxBiopharmaLDKLDK SolarLdkSolarNovavaxNVAXpre-market tradesPre-marketTradesRed HatRedHatRHTMon, 10 Dec 2007 08:27:00 EST<![CDATA[Hemispherx BioPharma: Does patience pay in Pharma?]]>http://www.bloggingstocks.com/2007/04/12/hemispherx-biopharma-does-patience-pay-in-pharma/http://www.bloggingstocks.com/2007/04/12/hemispherx-biopharma-does-patience-pay-in-pharma/http://www.bloggingstocks.com/2007/04/12/hemispherx-biopharma-does-patience-pay-in-pharma/#commentsFiled under:

Let's face it, small bio pharmaceutical companies are risky picks. But sometimes, you can pick one up at a very low price and watch it then develop into the next big thing in drugs and make you rich.

In December 2006, I blogged about Hemispherx BioPharma, Inc. (AMEX: HEB), one such small, risky pick -- but one that at the time, I felt was worth the gamble, simply because of the potential of a drug in the wings called Ampligen. HEB was about to file for FDA approval on this drug that has broad-spectrum anti-viral and anti-cancer properties and treats Chronic Fatigue Syndrome, among other illness.

Aside from the promise of Ampligen, I said there was little else at the time to recommend this company. However, its focus is a good one: Drugs treating viral and immune-based acute and chronic disorders like multiple sclerosis and West Nile Virus, along with AIDS, genital warts, hepatitis C, and acute respiratory syndrome.

Continue reading Hemispherx BioPharma: Does patience pay in Pharma?

Hemispherx BioPharma: Does patience pay in Pharma? originally appeared on BloggingStocks on Thu, 12 Apr 2007 16:05:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>HEBThu, 12 Apr 2007 16:05:00 EST